PDE4A and asthma: This article will discuss the evidence of roflumilast and other PDE4 inhibitors for treating chronic inflammatory airway disease beyond COPD including specific COPD phenotypes with comorbidities, severe asthma, noncystic fibrosis bronchiectasis, chronic rhinosinusitis, and treatment of chronic cough.